Jasper Therapeutics, Inc.
JSPR
$1.65
$0.074.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.89% | -25.81% | 12.66% | -30.50% | -27.80% |
| Total Depreciation and Amortization | -11.24% | -7.53% | 13.88% | -54.71% | 80.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.57% | 6.49% | -5.07% | -0.57% | 32.52% |
| Change in Net Operating Assets | -102.11% | 328.58% | -567.39% | -56.74% | 91.72% |
| Cash from Operations | -10.00% | 32.35% | -8.08% | -50.40% | -20.31% |
| Capital Expenditure | 100.00% | -- | -- | 64.96% | -74.52% |
| Sale of Property, Plant, and Equipment | -100.00% | 100.00% | -80.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -75.00% | 105.26% | 72.26% | -74.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 360.62% | -- | -- | 3,733.33% | -95.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 360.62% | -- | -- | 3,733.33% | -95.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 222.61% | 59.33% | -9.46% | -45.74% | -22.83% |